Systemic barriers block methamphetamine dependency treatment: Mirtazapine’s limited efficacy reveals gaps in harm reduction and structural healthcare inequities

Indigenous frameworks view addiction as a symptom of intergenerational trauma from colonization, land dispossession, and cultural erasure, not merely a biochemical imbalance. Traditional healing modalities—such as sweat lodges, plant medicines, and storytelling circles—address root causes of dependency by restoring communal and spiritual connections. Western pharmaceutical interventions often clash with these paradigms, as they individualize and pathologize what are collective wounds. The study’s focus on mirtazapine reflects a monocultural approach that dismisses time-tested indigenous methods of recovery.

The criminalization of methamphetamine in the 20th century mirrors historical drug panics tied to racialized minorities, from the U.S. anti-Chinese opium laws to South Africa’s apartheid-era policing of Black communities. Pharmaceutical interventions like mirtazapine are often repurposed from other crises, such as the opioid epidemic, revealing a pattern of reactive rather than preventive healthcare. The study’s emphasis on clinical trials ignores the failure of past 'miracle cures,' like methadone for heroin, which became tools of control rather than liberation. Historical precedents show that punitive drug policies exacerbate harm, while decriminalization reduces overdose deaths.

In Portugal, decriminalization of all drugs in 2001 shifted the focus from punishment to health, reducing HIV transmission and drug-related deaths by over 80%. Indigenous communities in Canada and Australia have successfully integrated traditional healing with Western medicine in addiction treatment, though these models are rarely funded or studied. In Vietnam, methamphetamine use is addressed through family and community networks, with lower relapse rates than in Western clinics that isolate individuals. These cross-cultural examples demonstrate that recovery is not solely a medical issue but a social and spiritual one.

The study’s methodology focuses on a single drug’s efficacy without examining the broader ecosystem of addiction, such as socioeconomic determinants, trauma histories, or social support systems. While mirtazapine shows promise in reducing cravings, its effectiveness is limited by high dropout rates and lack of long-term follow-up. Scientific consensus increasingly supports harm reduction over abstinence-only models, yet clinical trials often prioritize pharmaceutical solutions over community-based interventions. The study’s narrow scope reflects a biomedical reductionism that ignores the multifactorial nature of addiction.

Artistic expressions, from hip-hop to visual art, often depict methamphetamine use as a response to systemic oppression, loneliness, and unmet emotional needs, challenging the biomedical narrative. Spiritual practices—such as meditation, prayer, and nature-based rituals—have been shown to reduce relapse rates by addressing the existential void underlying addiction. The study’s clinical framing overlooks the role of creativity and spirituality in recovery, which are central to many non-Western healing traditions. Incorporating art therapy and spiritual guidance could enhance the efficacy of pharmaceutical treatments.

Future models must prioritize decriminalization, universal healthcare access, and housing stability to address the root causes of methamphetamine dependency. Scenario planning should include community-led recovery programs, such as peer support networks and land-based healing, which have proven more sustainable than clinical interventions. The rise of AI-driven addiction prediction tools risks further marginalizing vulnerable populations if not paired with equitable access and ethical oversight. Policymakers must shift from punitive models to harm reduction, as seen in Portugal’s successful decriminalization framework.

Methamphetamine dependency disproportionately affects Indigenous, Black, and low-income communities, yet these groups are underrepresented in clinical trials and policy discussions. The voices of sex workers, LGBTQ+ individuals, and homeless populations—who face higher rates of meth use—are systematically excluded from the narrative. Harm reduction programs led by and for these communities, such as syringe exchanges and overdose prevention sites, are often defunded despite their proven efficacy. The study’s focus on mirtazapine reflects a top-down approach that silences the lived experiences of those most impacted.